Vol. 497 No. 7
140 Ms Fitzgerald asked the Minister for Health and Children the further information available on patients given Amerscan Pulmonate II; if hospitals have a system in place of ensuring that ongoing information is given to these patients as new information becomes available; and if he will make a statement on the matter. [26202/98]
All traceable recipients of the Amerscan Pulmon ate II product batches that were withdrawn in November of last year have now been contacted by the hospitals involved and have either had or been offered appointments for follow-up consul tations with their treating physicians. The South ern Health Board is continuing in its efforts to contact one remaining patient whom it has had difficulty in tracing. I would like to acknowledge the work of all involved in the comprehensive programme of patient contact that has been involved, in particular the treating physicians who have facilitated this process so effectively. Any relevant new information that comes to light will be transmitted to the patients by these estab lished channels of contact through the treating physicians.
